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Abstract 
Background & Aims:   
Hepatitis C virus (HCV) therapies with interferon-free second-generation direct-acting 
antiviral agents (DAAs) are highly effective and well tolerated. They have the 
potential to increase treatment eligibility and efficacy in HIV-infected patients. We 
assessed the impact of DAAs on treatment uptake, efficacy as well as its impact on 
the burden of liver disease in the Swiss HIV Cohort Study (SHCS). 
 
Methods:  
We describe clinical and virological characteristics of patients treated with second 
generation DAAs. We compared treatment incidence, sustained virological response 
(SVR)12 and liver fibrosis stages between three time periods: period 1, 01/2009-
08/2011 (prior to the availability of DAAs); period 2, 09/2011-03/2014 (first generation 
DAAs); period 3, 04/2014-12/2015 (second generation DAAs).  
 
Results:  
At the beginning of the third period, 876 SHCS participants had a chronic HCV 
infection of whom 180 (20%) started treatment with a second generation DAA. Three- 
quarters of them had advanced liver fibrosis (Metavir≥3) of whom 80% were 
cirrhotics. SVR12 was achieved in 173/180 (96%) patients, 3 patients died and 4 
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experienced a virological failure. Over the three time periods, treatment uptake 
(4.5/100py, 5.7/100py, 22.4/100py) and efficacy (54%, 70%, 96% SVR12) 
continuously increased. The number of cirrhotic patients with replicating HCV 
infection in the SHCS declined from 25% at the beginning to 12% at the end of the 
last period.   
 
Conclusions:  
After the introduction of second generation DAAs we observed an increase in 
treatment uptake and efficacy which resulted in a significant reduction in the number 
of cirrhotic patients with replicating HCV infection in the SHCS. 
 
Key words: HCV treatment, uptake and efficacy, long-term trends, DAA, fibrosis 
 
Key points:  
 We observed a substantial increase in treatment uptake and efficacy  after the 
introduction of interferon-free second generation DAA treatments.  
 DAAs are well tolerated and highly efficacious, even among HIV/HCV-
coinfected patients with advanced liver fibrosis or cirrhosis.  
 The treatment of this population with advanced liver disease was driven by 
treatment priorities but also by limitations in reimbursement, and resulted in a 
significant reduction in the number of cirrhotic patients with replicating HCV.  
 The burden of replicating HCV infection can only be reduced if reimbursement 
is not restricted to those with advanced liver fibrosis. 
 
 
Introduction 
Hepatitis C virus (HCV) infection is a common and an important comorbidity in HIV-
infected patients1,2. Compared to HIV-monoinfected patients, HCV-coinfected 
patients have a higher risk for mortality3,4. In the Canadian coinfection cohort, 
EuroSIDA, as well as the Swiss HIV Cohort Study (SHCS), hepatic decompensation 
and hepatocellular carcinoma were among the most common causes of death in 
recent years5-7. Achieving a sustained virological response (SVR) substantially 
reduces HCV related mortality and morbidity and prevents further HCV 
transmission3,6,8. 
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For years, contraindications to interferon-based therapy, long treatment durations, 
fear of side-effects and reluctance of patients and physicians to start HCV treatment 
were frequent barriers to treatment9. In the SHCS only 12.5% of HIV/HCV-coinfected 
individuals started treatment with pegylated interferon (peg-IFN) and ribavirin (RBV) 
during a period of 4 years10. Fortunately, there have been major breakthroughs in the 
treatment of HCV infection with the approval of numerous direct-acting antiviral 
agents (DAAs). The addition of the first generation protease inhibitors (PIs) to peg-
IFN and RBV significantly increased rates of sustained virological response (SVR) in 
HCV genotype 1 infected patients11,12.  As these drugs still had to be combined to 
peg-IFN and RBV, only 13% of HCV genotype 1 infected patients started treatment 
after the approval of first generation PIs in Switzerland13. Thus these treatments only 
had a very modest impact on the burden of HCV disease at the population level. The 
new era of interferon-free second generation DAA improved safety and tolerability 
compared to previous interferon-based therapies. Accordingly, previously reported 
treatment barriers for peg-IFN/RBV therapy do not apply anymore in more than 60% 
of patients9. Cure rates above 90% are now achieved in all HCV genotypes and 
treatment efficacy is similar in HIV/HCV-coinfected patient compared to HCV-
monoinfected ones14.  
 
The World Health Organsization (WHO) defined ambitious targets with regard to viral 
hepatitis including a 65% reduction in mortality by 2030. To achieve this target, it is 
essential to understand the trends in HCV treatment uptake, and efficacy in real 
world settings. The SHCS provides an optimal framework to address the impact of 
DAAs in routine clinical practice in a nationwide representative HIV/HCV-coinfected 
population. The aims of this study were to assess the impact of new DAAs on 
treatment uptake and efficacy as well as its repercussion on liver disease burden in 
the SHCS. 
 
Patients and methods 
Study population: 
The SHCS (www.shcs.ch) prospectively enrolls HIV-infected adults in Switzerland 
since 1988. It includes 73% of all diagnosed HIV-infections in Switzerland15. 
Representativity has remained stable over the years. Detailed clinical and laboratory 
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data are recorded at study entry and every 6 months thereafter and include 
information on HCV serology, HCV RNA, transaminases, HCV treatment and liver 
related events (decompensation, variceal bleeding or hepatic encephalopathy, 
hepatocellular carcinoma, and liver-related death), as well as data on liver histology 
and transient elastography. Local ethical committees (KEK-BE: Kantonale 
Ethikkommission Bern, KEK-ZH Kantonale Ethikkommission Zürich, EKBB: 
Ethikkommission beider Basel, EKSG: Ethikkommission St. Gallen, CER-GE: 
Commission cantonale d’éthique de la recherche, CER-VD: Commission cantonale 
d’éthique de la recherché sur l’être humain, Comitato etico cantonale-TI) of all 
participating study sites have approved the study and written consent is obtained 
from all participants. All HCV-seropositive participants with positive HCV RNA and at 
least two visits were considered for this analysis, however, patients treated during 
acute HCV infection were excluded. 
 
Study periods: 
We defined 3 distinctive analysis  periods, based on the availability of HCV 
treatments in Switzerland: 
-Period 1, termed “peg-IFN/RBV era”, lasted from 01/2009-08/2011 and represents 
the period when DAAs were not yet available in Switzerland and patients were still 
treated with peg-IFN /RBV.  
-Period 2, termed “1st-generation DAA era” lasted from 09/2011-03/2014 and 
represents the period after the approval of first generation DAAs in Switzerland for 
HCV genotype 1 infections (boceprevir and telaprevir). 
-Period 3, termed “2nd-generation DAA era” lasted from 04/2014-12/2015 and 
represents the period after the approval of the first second generation DAA in 
Switzerland (sofosbuvir (SOF) in April 2014).  
 
Assessment of HCV treatment: 
Details on treatment safety, uptake and efficacy were assessed in all patients treated 
during period 3 (2nd-gen. DAA era). To analyze potential changes in the treated 
population over time we compared patients infected with HCV genotype 1 treated 
during period 2 (1st-gen. DAA era) and period 3 (2nd-gen. DAA era). Data on 
treatment uptake and efficacy form period 1 (peg-IFN/RBV era) and period 2 (1st-gen. 
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DAA era) were retrieved from our previous studies as well as from the SHCS 
database3,13. 
To capture the key events during HCV treatment, a case-report form was 
implemented from 2011 onwards, specifically designed to retrieve information that 
could have been missed with the 6-monthly follow-up visits. HCV viral loads were 
recorded at baseline, at treatment stop or treatment failure as well as 12 weeks after 
treatment stop. Treatment responses were defined according to the European 
Guidelines for the Study of the Liver (www.easl.eu). Sustained virological response 
was assessed at 12 weeks (SVR12) after treatment discontinuation and considered 
even after closure of the recruitment in December 2015. This avoided a systematic 
bias towards poorer outcomes, as those who failed or discontinued therapy 
prematurely were more likely to experience an endpoint within the study period. The 
treatment was at the discretion of the physician, however at the time SOF was 
approved in Switzerland, the treatment of chronic HCV with second generation DAAs 
was only reimbursed by Swiss health insurances for patients with advanced fibrosis 
(≥Metavir F3) or defined extrahepatic manifestations of chronic HCV infection. In 
August 2015, the reimbursement threshold was reduced to Metavir F2. 
 
Study measurements:  
Quantitative HCV RNA measurements were performed for all patients with the 
COBAS® TaqMan® HCV Test v2.0 on the COBAS AmpliPrep/TaqMan48 system 
(Roche Diagnostics International AG, Rotkreuz, Switzerland) according to 
the manufacturer’s protocol, with a lower limit of detection of 15 IU/mL. Genotypes 
were determined using TaqMan® Genotyping Master Mix (Life Technologies, 
Carlsbad, CA, USA). Where available, liver fibrosis stage was derived from liver 
biopsy and expressed as a Metavir score. Alternatively, liver fibrosis was determined 
using transient elastography (Fibroscan®; Echosens S.A.S.U., Paris, France). 
According to previous studies in HIV/HCV-coinfected patients, we used the following 
cut-off values: 7.1kPa for Metavir F2, 9.5 kPa for Metavir F3, and 12.4 kPa for 
Metavir F4 (cirrhosis)16.  
 
Statistical analysis: 
Demographic and clinical characteristics at HCV treatment start were described using 
absolute numbers and proportions, or medians and interquartile ranges (IQR) for 
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patients treated during period 3. Their main characteristics were compared to those 
of patients treated during period 2 using Chi-square, Fisher’s exact or Mann-Whitney 
test, where appropriate. All testing was two-tailed and P-values < 0.05 were 
considered to indicate statistical significance. Treatment uptake was described as 
incidence of treatment initiations by period. Treatment uptake and efficacy, as well as 
liver fibrosis stages were compared between different time periods using the Chi-
square test. Statistical analyses were performed using Stata Version 13.1. 
 
Results 
Characteristics of patients treated with 2nd generation DAAs 
At the beginning of the third period, 876 participants had a chronic HCV infection and 
of those 180 (20%) started treatment with a second generation DAA. At baseline, 
patients were predominantly middle-aged (median: 52 years [IQR 48-56]), Caucasian 
(166/180 [92%]) and males (124/180 [70%]) (Table 1). Most individuals were on ART 
(170/180 [70%]) and 99% of them had a suppressed HIV viral load. Three-quarters 
had a CD4 count > 350 cells/µl. One hundred and twelve of 180 (62%) were people 
who injected drugs (PWID) previously and 18% of them reported active consumption 
of illicit drugs. There was only a small proportion (9%) of men who have sex with men 
(MSM). Depression was diagnosed in one third of all patients. Transaminases were 
elevated [ACTG (AIDS Clinical Trials Group) grade 1-4] in 94/168 (56%) of the 
patients. Most patients were infected with HCV genotype 1 (55%), followed by 
genotype 3 (21%), genotype 4 (18%) and finally genotype 2 (2%). Among the treated 
patients, 76% had advanced fibrosis (≥Metavir F3). Cirrhosis was present in 62% of 
patients, of whom 85% had compensated cirrhosis (Child A). One hundred and sixty-
four of 180 (91%) patients were treated with a sofosbuvir (SOF) based regimen 
(Table 1), of whom 55% received the fixed combination of SOF/ ledipasvir (LDV). 
The combination of ombitasvir/ paritaprevir/ritonavir (OMV/PTV/RTV) and dasabuvir 
(DSV) was prescribed in 17/180 (9%). Additional ribavirin (RBV) was prescribed in 
one half of cases. Sixty-one percent (109/180) of the patients were treatment-
experienced, 97 with peg-IFN/RBV, 11 with a PI and 1 with SOF. In 88% of patients 
the indication to start treatment was liver fibrosis. From the 11 patients that started 
treatment because of extrahepatic manifestations, 3 had a vasculitis, 3 had a 
glomerulonephritis, 2 had a porphyria cutanea tarda, 2 had fatigue and 1 had a 
cryoglobulinemia.  
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Efficacy and safety of patients treated with 2nd generation DAAs 
Overall, 96% (95% confidence interval [CI], 93%-99%) of patients achieved an 
SVR12 (173/180) (Figure 1). Three patients treated with SOF and RBV had a 
virological relapse, 2 with a genotype 4 and one with a genotype 1A infection. One 
patient with genotype 3A experienced a virological breakthrough under a treatment 
with SOF and RBV. Detailed clinical, laboratory and treatment characteristics of 
these patients are summarized in Supplementary Table 1. Three patients died 
during treatment, 2 from liver decompensation and 1 from sepsis, all had cirrhosis 
and two of them had decompensated cirrhosis. Only one of 180 patients discontinued 
treatment. This patient  developed a clinically and laboratory significant 
rhabdomyolysis (maximal creatinkinase level of 3’052 U/L) without relevant renal 
complications five weeks after the initiation of SOF/LDV for a HCV genotype 1A 
infection with advanced fibrosis. The physician in charge judged this event as being 
potentially related to HCV therapy. The symptoms resolved after treatment 
withdrawal, and despite this only very short treatment duration he achieved SVR12.  
 
Characteristics of patients treated for HCV genotype 1 infection in period 3 
(2nd-gen. DAA era) compared to period 2 (1st-gen. DAA era)  
There were 99 patients with genotype 1 treated during period 3 and 57 during period 
2. Compared to patients treated during period 2, patients treated during period 3 
were slightly older (52 [IQR 47-56] vs. 48 [IQR 43-52]) (Table 2). No differences in 
laboratory values or HIV-related characteristics were noted between individuals 
treated in either one or the other period. Patients treated during period 3 were more 
likely to have advanced liver fibrosis [77/99 (77%) vs. 33/57 (58%) p<0.01],  or 
cirrhosis [63/99 (64%) vs. 20/57 (35%) p<0.01], compared to those treated during 
period 2. 
 
Changes in treatment uptake and efficacy over the three periods 
Overall treatment uptake continuously increased through the 3 periods (from 4.5 to 
5.7 to 22.4 per 100 patient-years), with a 4-fold increase after the introduction of 
second generation DAAs during period 3 (Figure 1). During period 2, treatment 
uptake increased only in HCV genotype 1 infected patients, whereas it diminished in 
all other genotypes. Treatment efficacy increased through the 3 periods  (SVR 12: 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
from 55% [95% CI, 44%-64%] to 70% [95% CI, 63%-79%] and 96% [95% CI, 93%-
99%]) and was observed among all genotypes.  
 
Changes in liver fibrosis stages over time 
At the end of the second period in April 2014 data on liver fibrosis stages was 
available for 623 patients with a chronic HCV infection in the SHCS (Figure 2). Of 
those, 33% (204/623) had advanced fibrosis (≥Metavir F3) of which158 (77%) had a 
cirrhosis. At the end of period 3, the proportion of patients with advanced fibrosis still 
to be treated declined to 15% (67/438) and only 12% (51/438) had a cirrhosis 
(p<0.01). 
 
Discussion 
After the approval of interferon-free second generation DAAs, we observed a 4-fold 
increase in treatment uptake and a 2-fold increase in treatment efficacy leading to 
SVRs above 90% across all HCV genotypes in the SHCS. Even traditionally difficult-
to-treat, pre-treated patients with advanced liver fibrosis achieved high SVR rates 
with DAA treatments in a clinical routine setting. Because of treatment priorities and 
reimbursement limitations, three-quarters of patients treated with second generation 
DAAs had advanced fibrosis. The successful treatment of these patients led to a 2-
fold reduction of patients with cirrhosis and a replicating HCV infection in the SHCS.  
 
As in the French  ANRS CO13-HEPAVIH cohort and the German hepatitis C cohort 
(GECCO), patients treated with second generation DAAs in the SHCS were 
predominantly middle aged, males, who previously injected drugs17,18. In our study 
three-quarters of them had advanced fibrosis and 60% were previously treated, 
traditionally representing the difficult-to-treat population (Table 1). Similar findings 
were described in the French cohort, with 73% cirrhotic patients and 70% who had 
failed previous treatment. Ninety percent of patients were treated with a SOF based 
regimen and of those 55% received the fixed combination of SOF/LDV in the SHCS, 
which contrasts with the French cohort where a regimen containing SOF/DCV was 
predominantly used (68%). In the SHCS second generation DAA treatments were 
highly effective, leading to an overall SVR12 rate of 96%. Similar overall SVR12 rates 
were found in the French (92%) and the German (96%) cohorts. These data confirm 
that efficacy in real world settings is similar to those found in registered trials,  with 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
response rates in HIV/HCV-coinfected patients similar to those in HCV-
moninfected19-22. All 3 patients who died during treatment had cirrhosis, two already 
being in a decompensated state. This underscores that the benefits of treatment are 
not universal, particularly in patients with decompensated cirrhosis and high MELD 
scores23. Similarly to the French cohort where only 4% of patients prematurely 
stopped their therapy, all DAA combinations were generally well tolerated in the 
SHCS, with only one patient having to discontinue treatment. This underscores the 
dramatic improvement of tolerability of second generation DAAs compared to 
previous treatments24,25. The four  virological failures in our study occurred among 
patients treated with only one DAA. Similarly, lowest cure rates were also described 
with the combination of SOF/RBV in the two other European cohorts, particularly 
among genotype 3 infected patients. 
 
Compared to patients treated in the 1st-generation DAA era, patients treated during 
the 2nd-generation DAA era had significantly higher fibrosis stages and twice as much 
patients were cirrhotics (Table 2). This reflects the improvements in treatment 
eligibility as contraindications to interferon-based therapy did not apply any more in 
the 2nd-generation DAA era. But it is also driven by treatment prioritization of those 
with advanced liver disease and by reimbursement restrictions according to the 
Metavir stage. 
 
We observed an increase in treatment uptake over time, especially in the last study 
period, when 2nd generation DAA were available. Treatment uptake in the peg-
IFN/RBV era was similarly low in the SHCS as in other European cohorts, ranging 
from 3.4 to 5.9 per 100 patient years 3,26,27. Before 2011, less than one third of 
HIV/HCV-coinfected patients in the SHCS were eligible for treatment and only a 
minority started treatment 9,10,28. Similar rates were found in a large registry of 99,166 
US veterans with HCV viremia, were only 11.6% started treatment, and 57% of those 
not treated had contraindications to treatment29. After the approval of first generation 
DAAs (PIs, only against genotype 1) in Switzerland in September 2011, only 13% of 
HCV genotype 1 infected patients started treatment and treatment incidence 
increased only slightly in routine clinical care (from 3.8 to 6.1 per 100 patient-years), 
thereby only having a very modest impact on the burden of HCV disease at the 
population level13. In this period, we noticed a decrease in treatment uptake across 
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all other genotypes (Figure 1), highlighting the fact that physicians postponed 
treatment awaiting for more efficient and more tolerable treatments for non-1 
genotype infected individuals. In the 2nd generation DAA era, we observed an 
impressive fourfold increase in treatment uptake, reaching a treatment incidence of 
22 per 100 patient-years, which is close to the 25 per 100 patient-years found in 
EuroSIDA30. 
 
As a consequence of the improvement in treatment tolerability and efficacy, and 
because of treatment priorities and reimbursement limitations, three-quarters of 
patients treated in the 2nd-generation DAA era had advanced fibrosis. This led to a 
twofold reduction of cirrhotics with a replicating HCV infection in the SHCS from April 
2014 to December 2015. Close monitoring of patients treated at a stage of advanced 
liver disease is warranted, as these are at ongoing risk of experiencing liver-related 
events, particularly HCC. The combination of the increasing treatment uptake and 
efficacy, as well as the treatment of a large proportion of patients with advanced liver 
disease should contribute to the reduction of the HCV disease burden in the near 
future31. Moreover, we demonstrated previously, that this increase in treatment 
uptake combined with stabilization in risk behavior can efficiently reduce HCV 
transmission32.  However because of reimbursement limitations only very few MSM 
with high risk behavior could be treated because they often had low fibrosis stages. 
As the remaining patients to be treated often have mild fibrosis, the burden of 
replicating HCV infection will only be further reduced if reimbursement is not 
restricted to those with advanced fibrosis. Unfortunately, universal access to HCV 
therapy is restricted to few countries worldwide due to the huge costs of these 
treatments33. The successful negotiations with pharmaceutical companies in 
Australia and Egypt to substantially lower DAA costs exemplify that this can be 
achieved. 
 
We report on one of the largest prospective observational studies assessing long-
term HCV treatment uptake and outcomes in HIV-infected individuals. The detailed 
and systematic clinical and biological monitoring within the SHCS provided detailed 
information on treatment safety, efficacy as well as on liver fibrosis stages and 
allowed us to compare these parameters over different time periods. But this study 
also has limitations. The continuous approval of new drugs as well as changes in 
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guidelines and reimbursement policies over time resulted in a heterogeneity of 
treatments used, precluding comparisons between different treatment regimens. 
Rather than comparing the safety and efficacy of different regimens, our study 
focused on the description of the overall uptake, efficacy and tolerability of HCV 
therapy in routine clinical practice. As  treatment uptake is directly linked to 
reimbursement policies, our data might not be generalizable to settings with different 
regulations.  
 
In conclusion, we observed a substantial increase in treatment uptake and efficacy  
after the approval of interferon-free second generation DAA treatments. DAAs were 
well tolerated and highly efficacious, even among HIV/HCV-coinfected patients with 
advanced liver fibrosis or cirrhosis in the SHCS. The treatment of this population with 
advanced liver disease was driven by treatment priorities but also by limitations in 
reimbursement, and resulted in a significant reduction in the number of cirrhotic 
patients with replicating HCV. However many with mild fibrosis are still untreated. 
Thus, we will only be able to further reduce the burden of replicating HCV infection if 
reimbursement is not restricted to those with advanced fibrosis. 
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Figure 1: Treatment uptake and efficacy over the 3 periods.  
(period 1: peg-IFN/RBV era, 01/2009-08/2011 ; period 2: 1st-gen. DAA era, 09/2011-
03/2014; period 3: 2nd-gen. DAA era, 04/2014-12/2015)  
Abreviations: py, patient years; GT, genotype; SVR, sustained virological response 
 
Figure 2: Distribution of liver fibrosis among patients with active HCV infection in the 
different periods 
At the end of period 2 in April 2014, 876 patient had a chronic HCV infection. In December 2015 at the 
end of Period 3, 692 patients had a  chronic HCV infection.  
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Table 1: Baseline characteristics of all patients of the SHCS treated during period 3 (2nd-generation 
DAA era) 
 
N  
All treatment 
180 
Demographic characteristics 
Age, median (IQR) 
Male (%) 
Caucasian (%) 
Illicit drug use (%) 
Depression (%) 
 
52 (48-56) 
124/180 (70) 
166/180  (92) 
20/180  (11) 
53/180  (29) 
HIV characteristics  
Median HIV RNA in log cp/ml (IQR) 
Controlled HIV RNA<20 copies/ml (%) 
Patients on ART (%) 
CDC Stage C (%) 
Median CD4 in cells/ul (IQR) 
CD4 cell category (cells/ul) 
    1-200 
    200-350 
    >350 
HIV Transmission group (%) 
    MSM 
    IDU 
    HET 
    Other 
 
0 (0-0) 
168/180 (93) 
170/180 (94) 
64/180 (36) 
508 (467-749) 
 
16/180 (9) 
26/180 (15) 
138/180 (76) 
 
17/180  (9) 
112/180  (62) 
37/180  (21) 
14/180  (8) 
Laboratory values 
Median eGFR in ml/min (IQR)* 
Median Thrombocytes in G/L (IQR) 
Liver Enzymes, median (IQR) 
ALT (U/L) 
AST (U/L) 
ALT elevation** (%) 
 
94 (74-104) 
141 (95-182) 
 
58 (36-101) 
57 (39-91) 
94/168 (56) 
Hepatitis C characteristics 
HCV viral load (log10 copies/ml), median (IQR) 
HCV Genotype (%) 
   GT 1 
   GT 2 
   GT 3 
   GT 4 
Liver Fibrosis stage (%) 
   F0-1 
   F2 
   F3 
   F4 
 
6.1 (5.4-6.5) 
 
99/180 (55) 
4/180 (2) 
37/180 (21) 
32/180 (18) 
 
22/180 (12) 
21/180 (12) 
25/180 (14) 
112/180 (62) 
Treatment 
SOF (%) 
    SOF LDV  
    SOF DCV 
    SOF SIM 
    SOF IFN 
OMV/PTV/RTV + DSV(%) 
Ribavirin (%) 
Treatment history (%) 
    Treatment naïve 
    Experienced 
Treatment indication (%) 
    Fibrosis 
    Extrahepatic manifestations 
    Other 
 
164/180 (91) 
90/180  
24/180 
6/180 
17/180 
16/180  (9) 
88/180  (49) 
 
71/180 (39) 
109/180 (61) 
 
159/180 (88%) 
11/180 (6%) 
10/180 (6%) 
Abbreviations: SHCS, Swiss HIV Cohort Study; IQR, interquartile range; MSM, men who have sex with men; IDU, injection drug user; HET, 
heterosexual; HIV, human immunodeficiency virus; ART, antiretroviral therapy; CDC, Centers for Disease Contorl; eGFR, estimated 
glomerular filtration rate;  ALT, alanin-Aminotransferase; AST, aspartate-aminotransferase; HCV, hepatitis C virus; GT; 
genotype; SOF, sofosbuvir; LDV, ledipasvir; DCV, daclatasvir; SIM, simeprevir; INF, interferon; OMV, 
ombitasvir; PTV, paritaprevir; RTV, ritonavir; DSV, dasabuvir 
*eGFR: calculated with the CKD-EPI formula 
**ACTG (AIDS Clinical Trials Group) Grade 1-4  
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Table 2: Comparison of genotype 1 treated patients between period3 (2nd-generation DAA era) and 
period 2 (1st-generation DAA era) 
 
N  
Period 2 
57 
Period 3 
99 
Demographic characteristics 
Age, median (IQR) 
Male (%) 
Caucasian (%) 
Illicit drug use (%) 
Depression (%) 
 
48 (43-52) 
47/57 (82) 
51/57 (89) 
7/57 (12) 
13/57 (23) 
 
52 (47-56) 
71/99 (73) 
91/99 (92) 
14/99 (14) 
31/99 (31) 
HIV characteristics  
Median HIV RNA in log cp/ml (IQR) 
Controlled HIV RNA<20 copies/ml (%) 
Patients on ART (%) 
CDC Stage C (%) 
Median CD4 in cells/ul (IQR) 
CD4 cell category (cells/ul) 
    1-200 
    200-350 
    >350 
HIV Transmission group (%) 
    MSM 
    IDU 
    HET 
    Other 
 
 
50/57 (88) 
54/57 (95) 
20/57 (35) 
496 (380-697) 
 
4/57 (7) 
8/57 (14) 
45/57 (79) 
 
11/57  (19) 
33/57  (58) 
8/57  (14) 
5/57  (9) 
 
 
95/99 (96) 
93/99 (94) 
36/99 (36) 
521 (408-800) 
 
4/99 (4) 
16/99 (16) 
79/99 (80) 
 
10/99 (10) 
60/99 (61) 
20/99 (20) 
9/99 (9) 
Laboratory values 
Median eGFR in ml/min (IQR)* 
Median Thrombocytes in G/L (IQR) 
Liver Enzymes, median (IQR) 
ALT (U/L) 
AST (U/L) 
ALT elevation** (%) 
 
100 (86-108) 
156 (104-226) 
 
50 (33-76) 
45 (36-59) 
27/57 (47) 
 
93 (77-104) 
140 (105-174) 
 
50 (36-94) 
50 (34-87) 
45/99 (45) 
Hepatitis C characteristics 
HCV viral load (log10 copies/ml), median (IQR) 
Liver Fibrosis stage (%) 
   F0-1 
   F2 
   F3 
   F4 
 
6.1 (5.1-6.4) 
 
10/57 (17) 
14/57 (24) 
13/57 (23) 
20/57 (35) 
 
6.1 (5.6-6.5) 
 
10/99 (10) 
12/99 (12) 
14/99 (14) 
63/99 (64) 
Abbreviations: SHCS, Swiss HIV Cohort Study; IQR, interquartile range; MSM, men who have sex with men; IDU, injection drug user; HET, 
heterosexual; HIV, human immunodeficiency virus; ART, antiretroviral therapy; CDC, Centers for Disease Contorl; eGFR, estimated 
glomerular filtration rate;  ALT, alanin-Aminotransferase; AST, aspartate-aminotransferase; HCV, hepatitis C virus;  
*eGFR: calculated with the CKD-EPI formula 
**ACTG (AIDS Clinical Trials Group) Grade 1-4  
 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
